Tenaya Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
10 août 2022 16h01 HE
|
Tenaya Therapeutics, Inc.
Received State Licensing to Enable cGMP Manufacturing of Drug Product TN-201 and TN-301 IND Submissions on Track for Second Half 2022 Presented Preclinical Data for Multiple Pipeline Programs and...
Tenaya Therapeutics Publishes Preclinical Data in Science Translational Medicine Detailing Discovery of HDAC6 Inhibitor for Treatment of Heart Failure
06 juil. 2022 14h00 HE
|
Tenaya Therapeutics, Inc.
Tenaya’s Precision Medicine Platform Used to Identify HDAC6 Target Using Phenotypic Screening and Machine Learning Algorithms Tenaya’s HDAC6 Inhibitor TN-301 Advancing to the Clinic for HFpEF, with...